Cargando…
A pilot clinical study of apatinib plus irinotecan in patients with recurrent high-grade glioma: Clinical Trial/Experimental Study
BACKGROUND: Malignant glioma is the most common primary malignant brain tumor that displays high vascularity, making vascular endothelial growth factor receptors become promising targets. This study was conducted to evaluate the efficacy and safety of apatinib, a new potent oral small-molecule tyros...
Autores principales: | Wang, Lei, Liang, Lijun, Yang, Tao, Qiao, Yun, Xia, Youyou, Liu, Liang, Li, Chao, Lu, Peizhi, Jiang, Xiaodong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728925/ https://www.ncbi.nlm.nih.gov/pubmed/29245310 http://dx.doi.org/10.1097/MD.0000000000009053 |
Ejemplares similares
-
Apatinib concurrent gemcitabine for controlling malignant ascites in advanced pancreatic cancer patient: A case report
por: Liang, Lijun, et al.
Publicado: (2017) -
S-1 plus apatinib followed by salvage esophagectomy for irinotecan-refractory small cell carcinoma of the esophagus: A case report and review of the literature
por: Zhang, Chu, et al.
Publicado: (2020) -
Radiotherapy with apatinib for recurrence of malignant phyllodes tumor of the breast: A case report
por: Wu, Hong, et al.
Publicado: (2020) -
Neoadjuvant apatinib plus S-1 in locally advanced pulmonary adenocarcinoma: A case report and review of the literature
por: Zhang, Chu, et al.
Publicado: (2020) -
Apatinib plus retinoic acid as maintenance for children with relapsed stage 4 high-risk neuroblastoma: Two case reports
por: Jin, Mei, et al.
Publicado: (2020)